This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 90.48%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 90.5% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -1.02% and 11.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Rapt Therapeutics (RAPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Rapt Therapeutics (RAPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Factors to Note Ahead of Hewlett Packard (HPE) Q1 Earnings
by Zacks Equity Research
Hewlett Packard's (HPE) fiscal first-quarter results are likely to reflect gains from growing demand for its cloud services amid the ongoing digital transformation trend.
Wall Street Analysts See a 57.57% Upside in Rapt Therapeutics (RAPT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 57.6% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Factors to Note Ahead of Zscaler's (ZS) Q2 Earnings Release
by Zacks Equity Research
The increased demand for security and networking products amid the ongoing hybrid work environment and digitization process is likely to have aided Zscaler's (ZS) second-quarter performance.
What Makes Rapt Therapeutics (RAPT) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Rapt Therapeutics (RAPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -5.56% and 66.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions (EBS) Moves 12.5% Higher: Will This Strength Last?
by Zacks Equity Research
Emergent Biosolutions (EBS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 66.77%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Rapt Therapeutics (RAPT) points to a 66.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why 'Trend' Investors Would Love Betting on Rapt Therapeutics (RAPT)
by Zacks Equity Research
Rapt Therapeutics (RAPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Does Rapt Therapeutics (RAPT) Have the Potential to Rally 122% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Rapt Therapeutics (RAPT) points to a 122.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why RAPT Therapeutics (RAPT) Stock Might be a Great Pick
by Zacks Equity Research
RAPT Therapeutics (RAPT) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 116%
by Zacks Equity Research
The consensus price target hints at an 115.5% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of 3.08% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -197.29% and 33.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Q3 Earnings Miss Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of -9.09% and 2.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Rapt Therapeutics (RAPT) Looks Ripe for Bottom Fishing
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Rapt Therapeutics (RAPT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 74%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 73.7% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Can Rapt Therapeutics (RAPT) Climb 59% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 58.9% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Rapt Therapeutics (RAPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of 17.33% and 121.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0% and 48.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 15% and 117.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) Moves 4.4% Higher: Will This Strength Last?
by Zacks Equity Research
Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.